Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IGLV3-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV3-1 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV3-1 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV2-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV2-8 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV2-8 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV3-10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV3-10 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV3-10 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV2-23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV2-23 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV2-23 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV2-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV2-11 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV2-11 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV2-18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV2-18 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV2-18 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV2-14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV2-14 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV2-14 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV10-54 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV10-54 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV10-54 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV11-55 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV11-55 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV11-55 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV1-44 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV1-44 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV1-44 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV1-51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV1-51 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV1-51 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
IGLV1-47 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
IGLV1-47 Biologics Sequence Review Report 2026: Similarity and Patent-Risk Signals
16 October 2026
A Biology Modality MCP review of IGLV1-47 sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →